ASP8477 in Peripheral Neuropathic Pain (MOBILE)
Research type
Research Study
Full title
A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain
IRAS ID
138308
Contact name
David Pang
Contact email
Sponsor organisation
Astellas Pharma Europe B.V. (APEB)
Eudract number
2013-002521-27
ISRCTN Number
n/a
Research summary
Neuropathic pain is a type of pain which is caused by damage to or dysfunction of the nervous system. Characteristic for neuropathic pain is the experience of both painful abnormal sensations (paresthesia) and unpleasant abnormal sensations(dysesthesia). Spontaneous pain such as burning, tingling, itching and aching often coexist with evoked pain such as shooting, stabbing or electric pains.
Drugs that are often used for peripheral neuropathic pain relief are associated with certain side effects. Astellas has developed a drug with the code number ASP8477 to treat neuropathic pain possibly without the side effects associated with the drugs that are commonly used to relieve neuropathic pain. The purpose of this study is to evaluate how well ASP8477 relieves pain and how safe ASP8477 is in
subjects with peripheral neuropathic pain. ASP8477 is not an approved product.
The information collected in this study is necessary to find out whether the treatment tested is effective and safe.REC name
London - Chelsea Research Ethics Committee
REC reference
14/LO/0031
Date of REC Opinion
29 Apr 2014
REC opinion
Further Information Favourable Opinion